Relationship between BCR-ABL IS and Prognosis and Affecting Factors for Prognosis in CML Patients Treated with TKI for 12 Months

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 26; no. 5; p. 1281
• Main Authors: Hu, Chen-Yuan, Yu, Di, Zhan, Bing, Han, Ya-Hui, Zhang, Huan-Xin, Li, Zhen-Yu, Zeng, Ling-Yu, Yan, Zhi-Ling, Xu, Kai-Lin
• Format: Journal Article
• Language: Chinese
• Published: China 01.10.2018
• Subjects: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Survival Analysis
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2018.05.005

To evaluate the long-term prognosis of CML patients whose BCR-ABL transcript level was warning and best response at 12 months of treatment with tyrosine kinase inhititor (TKI), and to investigate the factors affecting therapeutic efficacy and prognosis. The clinical data of patients with newly diagnosed CML were analyzed retrospectively. According to BCR-ABL transcript level, the 80 patients were divided into group A and group B, the patients with BCR-ABL >0.1% and ≤ 1% (warning response) were entolled in group A, and the patients with BCR-ABL ≤ 0.1% (best response) were enrolled in group B as control. The ratio of patients with main molecular response (MMR) and deep molecular response (DMR), as well as aquistation rate and cummulative rate of MR (DMR) at specified fine points in 2 groups were compared, the independent risk factors affecting the therapeutic efficacy and prognosis were analyzed. The MMR and MR of the B group at 15, 18 and 24 months after TKI treatment were significantly higher than those of th